French biotechnology company TxCell has appointed Biogen’s Dr Olivier Danos to its scientific advisory board.
Since 2014, Dr Danos has served as senior vice president of cell and gene therapy at Biogen, leading its research group to develop new technologies for gene transfer and genome engineering.
Before to taking up this role in 2011, Dr Danos was Kadmon Pharmaceutical’s senior vice president for molecular science, synthetic biology and gene regulation, where he led the creation of its gene therapy and technology platforms.
He has also served as director of the Gene Therapy Consortium at University College London, scientific director of Généthon, and senior research director for France’s National Centre for Scientific Research (CNRS).
Arnoud Foussat, chief scientific officer at TxCell, said: “Dr Olivier Danos has pioneered technologies of central importance in the field of gene therapy and genome editing.
“He is another significant addition to our scientific advisory board, which already includes leading experts in immunology, T-cell biology and chimeric antigen receptors.
“We are looking forward to their insights and advice on our current and future research and development programmes targeting severe chronic autoimmune and inflammatory diseases.”